Cookie Einstellungen
Diese Webseite verwendet ausschließlich notwendige Cookies, die für die Funktion erforderlich sind. Marketing- und Statistik-Cookies kommen nicht zum Einsatz. Weitere Informationen finden Sie in unserer Datenschutzerklärung.
 Notwendig   Details einblenden
      OK      
Bitte logge Dich ein, um diese Funktion zu nutzen!
      OK      
x
Impact News +++ Meridian Mining Plc: Meridian Updates on Cabaçal′s Advancement Towards Final Investment Decision (Newsfile) +++ MERIDIAN MINING Aktie +5,31%

ANI PHARMA Aktie

 >ANI PHARMA Aktienkurs 
60.75 EUR    (TradegateBSX)
Ask: 61.5 EUR / 49 Stück
Bid: 60 EUR / 51 Stück
Tagesumsatz: 0 Stück
Realtime Kurs von 7:30 bis 22 Uhr!
ANI PHARMA Aktie über LYNX handeln
>ANI PHARMA Performance
1 Woche: -6,2%
1 Monat: -4,3%
3 Monate: -14,7%
6 Monate: -16,4%
1 Jahr: -23,3%
laufendes Jahr: -12,9%
>ANI PHARMA Aktie
Name:  ANI PHARMACEUT. DL-,0001
Land:  USA
Sektor:  Gesundheit
ISIN/ Wkn:  US00182C1036 / A1W15D
Symbol/ Ticker:  BSFA (Frankfurt) / ANIP (NASDAQ)
Kürzel:  FRA:BSFA, ETR:BSFA, BSFA:GR, NASDAQ:ANIP
Index:  -
Webseite:  https://anipharmaceutical..
Profil:  ANI Pharmaceuticals, Inc. is a biopharmaceutical company that develops, manufactures, and commercializes branded, generic, and specialty prescription medicines. ANI Pharmaceuticals focuses on three main areas: Rare Disease, Generics, and Established ..
>Volltext..
Marktkapitalisierung:  1477.38 Mio. EUR
Unternehmenswert:  1684.42 Mio. EUR
Umsatz:  878.24 Mio. EUR
EBITDA:  194.17 Mio. EUR
Nettogewinn:  89.72 Mio. EUR
Gewinn je Aktie:  4.32 EUR
Schulden:  548.01 Mio. EUR
Liquide Mittel:  323.38 Mio. EUR
Operativer Cashflow:  170.07 Mio. EUR
Bargeldquote:  1.33
Umsatzwachstum:  35.02%
Gewinnwachstum:  -
Dividende je Aktie:  -
Dividendenrendite:  -
Dividendenschätzung:  -
Insiderhandel:  3 Insider verkauften innerhalb der letzten 30 Tage Aktien im Wert von 567.188 Euro.
Suchwörter:  ANI PHARMA, ANI PHARMACEUTICALS
Letzte Datenerhebung:  09.11.26
>ANI PHARMA Kennzahlen
Aktien/ Unternehmen:
Aktien: 22.96 Mio. St.
Frei handelbar: 87.91%
Leerverk. Aktien: 15.12%
Rückkaufquote: 0.6%
Mitarbeiter: 970
Umsatz/Mitarb.: 0.82 Mio. EUR
Analysten:
Analystenrating: Buy
Kursziel: 45.87%
Bewertung:
KGV: 15.65
KGV lG: 7.69
KUV: 1.62
KBV: 2.79
PEG-Ratio: -
EV/EBITDA: 8.68
Rentabilität:
Bruttomarge: 51.63%
Gewinnmarge: 10.22%
Operative Marge: 13.34%
Managementeffizenz:
Gesamtkaprendite: 7.05%
Eigenkaprendite: 19.33%
>ANI PHARMA Peer Group
Gesundheit, Augenmedizin/ Sehhilfen, Rheuma- Behandlung, Neurologische Erkrankungen/ Schlaganfälle, Lungen- & Atemwegserkrankungen/ -behandlung
 
05.11.26 - 21:01
 ANI Pharma (ANIP) Q3 2026 Earnings Call Transcript (Fool)
 
Revenue rose 28% as ANI plans a $560 million Egetis acquisition....
05.11.26 - 14:57
 Für 10 Milliarden Dollar: Astrazeneca vor dem nächsten Übernahme-Hammer? (Der Aktionaer)
 
Mit dem Start in den November scheint das Übernahmekarussell im Biotech-Sektor wieder in Schwung zu kommen. Ani Pharmaceuticals will sich mit der Übernahme der schwedischen Egetis Therapeutics für 560 Millionen Dollar im Bereich der seltenen Erkrankungen verstärken....
05.11.26 - 13:00
 ANI Pharmaceuticals beats top-line and bottom-line estimates; narrows FY26 outlook (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
05.11.26 - 12:54
 ANI Pharmaceuticals Reports Third Quarter 2026 Financial Results (GlobeNewswire EN)
 
PRINCETON, N.J., Nov. 05, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today announced financial results and business highlights for the third quarter ended September 30, 2026....
05.11.26 - 12:54
 ANI Pharma to buy Swedish biotech Egetis for $560M (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
05.11.26 - 12:51
 REPEAT – ANI Pharmaceuticals Announces Offer to Acquire Egetis Therapeutics, Expanding the Scope and Scale of Its Rare Disease Business (GlobeNewswire EN)
 
PRINCETON, N.J., Nov. 05, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (“ANI” or the “Company”) announces a recommended public offer to acquire Egetis Therapeutics AB (publ) (“Egetis”) (the “Offer”)....
05.11.26 - 07:36
 ANI Pharmaceuticals Announces Offer to Acquire Egetis Therapeutics, Expanding the Scope and Scale of Its Rare Disease Business (GlobeNewswire EN)
 
PRINCETON, N.J., Nov. 05, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (“ANI” or the “Company”) announces a recommended public offer to acquire Egetis Therapeutics AB (publ) (“Egetis”) (the “Offer”)....
05.11.26 - 07:01
 ANI Pharmaceuticals announces a recommended cash offer to the shareholders and to the holder of the Convertible and the Warrants of Egetis Therapeutics (Cision)
 
This announcement is not an offer, whether directly or indirectly, in Australia, Canada, Hong Kong, Japan, New Zealand or South Africa or in any other jurisdiction where such offer pursuant to legislation and regulations in such relevant jurisdiction would be prohibited by applicable law. Shareholders and holder of the Convertible and the Warrants not resident in Sweden who wish to accept the Offer (as defined below) must make inquiries concerning applicable legislation and possible tax consequences. Shareholders and holder of the Convertible and the Warrants should refer to the offer...
03.11.26 - 12:57
 ANI Pharmaceuticals to Present at Upcoming November Investor Conferences (GlobeNewswire EN)
 
PRINCETON, N.J., Nov. 03, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today announced that Nikhil Lalwani, President and Chief Executive Officer, along with members of the Company's executive leadership team, will participate in presentations and fireside chats at the following upcoming investor conferences:...
30.10.26 - 23:01
 Insiderhandel: SVP & CFO verkauft Aktien von ANI Pharmaceuticals im Wert von 207680 USD (Insiderkauf)
 
Carey, Stephen P. - Vorstand - Tag der Transaktion: 2026-10-29...
23.10.26 - 12:57
 ANI Pharmaceuticals to Discuss Third Quarter 2026 Financial Results on November 5, 2026 at 8:00 a.m. ET (GlobeNewswire EN)
 
PRINCETON, N.J., Oct. 23, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today announced that the Company will release its third quarter 2026 financial results on Thursday, November 5, 2026, at 8:00 a.m. ET....
19.10.26 - 12:57
 ANI Pharmaceuticals Announces the Launch of Duloxetine Delayed-Release Capsules (GlobeNewswire EN)
 
PRINCETON, N.J., Oct. 19, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced the launch of Duloxetine Delayed-Release Capsules 20, 30 and 60 mg. ANI's Duloxetine Delayed-Release Capsules are the generic version of the reference listed drug (RLD) Cymbalta®....
17.10.26 - 02:01
 Insiderhandel: PRESIDENT & CEO verkauft Aktien von ANI Pharmaceuticals im Wert von 388206 USD (Insiderkauf)
 
Lalwani, Nikhil - Vorstand - Tag der Transaktion: 2026-10-15...
14.10.26 - 05:01
 Insiderhandel: SR. VP, GENERAL COUNSEL & SEC. verkauft Aktien von ANI Pharmaceuticals im Wert von 36795 USD (Insiderkauf)
 
Cook, Meredith - Vorstand - Tag der Transaktion: 2026-10-13...
12.10.26 - 17:42
 ANI Pharma reports positive phase 4 data for Iluvien in non-infectious uveitis (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
12.10.26 - 12:57
 ANI Pharmaceuticals Announces Positive Phase 4 Open-Label, Single-Arm SYNCHRONICITY Clinical Trial Results Presented as Late Breaking Oral Presentation at the American Academy of Ophthalmology 2026 Annual Meeting (GlobeNewswire EN)
 
ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today announced that both 6-month and 24-month data from SYNCHRONICITY, its Phase 4, open-label, single-arm clinical trial of Fluocinolone Acetonide Intravitreal Implant in patients with chronic non-infectious uveitis affecting the posterior segment of the eye (chronic NIU-PS) were presented in a late-breaking oral presentation during Uveitis Subspecialty Day 2026 on October 9, 2026 by Dr. David R.P. Almeida, MD, MBA, PhD, President and CEO of Erie Retina Research, and Principal Investigator in SYNCHRONICITY, at the American Academy of Ophthalmology (AAO) 2026 Meeting in New Orleans....
01.10.26 - 04:01
 Insiderhandel: SVP & CFO verkauft Aktien von ANI Pharmaceuticals im Wert von 208050 USD (Insiderkauf)
 
Carey, Stephen P. - Vorstand - Tag der Transaktion: 2026-09-29...
30.09.26 - 12:57
 ANI Pharmaceuticals Announces New Fluocinolone Acetonide Intravitreal Implant Data to be Presented at the American Academy of Ophthalmology 2026 Annual Meeting (GlobeNewswire EN)
 
Data from Phase 4 Open-Label, Single-Arm SYNCHRONICITY Trial will be presented in a late-breaking oral presentation during Uveitis Subspecialty Day 2026...
28.09.26 - 19:00
 Implied Volatility Surging for ANI Pharmaceuticals Stock Options (Zacks)
 
Investors need to pay close attention to ANIP stock based on the movements in the options market lately....
23.09.26 - 12:57
 ANI Pharmaceuticals Announces the FDA Approval of Everolimus Tablets for Oral Suspension (GlobeNewswire EN)
 
PRINCETON, N.J., Sept. 23, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that it received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA), for Everolimus Tablets for Oral Suspension 2mg, 3mg and 5mg. ANI's Everolimus Tablets for Oral Suspension are the generic version of the reference listed drug (RLD) Afinitor Disperz®....
>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!
Zitat des Tages: Es gibt Tage, da geht alles schief. Umso schöner ist es, wenn man weiß, daß man bedingungslos geliebt wird. - James Morgan
>Aktienauflistung | >Aktienscreener | >Aktienkennzahlen | >Anleihen | >ETFs | >Fonds | >Branchen | >Länder | >Themen | >Redaktionen
Partner:    >TradegateBSX Börse | >TradingView | >Boersentreff- Partner

Börsentreff auf Facebook | Börsentreff auf X | Börsentreff auf Instagram

Copyright @ Boersentreff.de - Die Märkte im Blick!